BioAge Labs, Inc. (BIOA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$257.5M
Cash & Equivalents
$24.1M
Quarterly Burn Rate
32 mo
Est. Cash Runway
$1,082M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-30 | Phase2 Readout | — |
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07656727 | A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Ca... | PHASE2 | Recruiting | 160 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.